Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bexicaserin by Longboard Pharmaceuticals for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Bexicaserin is under clinical development by Longboard Pharmaceuticals and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of...
Bexicaserin by Longboard Pharmaceuticals for Tuberous Sclerosis: Likelihood of Approval
Bexicaserin is under clinical development by Longboard Pharmaceuticals and currently in Phase II for Tuberous Sclerosis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Longboard Pharmaceuticals's Bexicaserin?
Bexicaserin is a small molecule commercialized by Longboard Pharmaceuticals, with a leading Phase II program in Lennox-Gastaut Syndrome. According to...
LP-659 by Longboard Pharmaceuticals for Neuroinflammation: Likelihood of Approval
LP-659 is under clinical development by Longboard Pharmaceuticals and currently in Phase I for Neuroinflammation. According to GlobalData, Phase I...